RegenLife’s innovative technology also relies on the emission of three light sources: red diodes, infrared and lasers (DR).
Based in Montpellier and Paris, this medtech has just raised 3 million euros from its historical partners and new private investors, to pursue its R&D and clinical trials against Alzheimer’s disease and sports-related concussions.
Using photobiomodulation technologies – in other words, light stimulation – to treat neurodegenerative diseases. To accelerate on this innovative path, medtech RegenLife, based in Montpellier and Paris, is initiating two decisive clinical studies on concussion and Alzheimer’s disease, financed by a €3 million fund-raising round from its historical partners and new private investors active in the field.
